Call Girls Visakhapatnam Just Call 9907093804 Top Class Call Girl Service Ava...
Hanipsych ssri
1.
2. Selective Serotonin Reuptake
Inhibitors
Prof. Hani Hamed Dessoki, M.D.Psychiatry
Prof. Psychiatry
Chairman of Psychiatry Department
Beni Suef University
Supervisor of Psychiatry Department
El-Fayoum University
APA member
3. Management
Management: Adjust dosage for
optimum benefit, safety and
compliance. Use adjunctive and
combination therapies if needed
however always strive for the
simplest regimen. Keep your
therapeutic endpoint in mind.
4. Why do we still need to talk about treating
depression?
In the good old days…
SSRIs were hailed as the cure for
everyone
Few SSRIs on the market, all
considered equally efficacious
Where we are today
The burden of depression is
increasing
Depression is still under-recognised
and undertreated
Many treated patients do not achieve
remission and risk relapse
How should the patient be treated and
monitored to obtain remission?
Nelson. Am J Psychiatry 2006; 163: 11: 1864–1866 4
6. What is required for full remission?
The patient perspective
Patients definition of remission:
• Positive mental health (e.g. optimism
and self-confidence)
• Return to one’s usual, normal self
• Return to usual level of functioning
• Absence of depressive symptoms
Symptomatic improvement vs functional improvement – a question
of timing ?
Are rating scales linked to functionality ?
Zimmerman et al., Am J Psychiatry 2006; 163:148–150)
6
7. Defining treatment goals
Outcomes are now
here
Ideal outcome
should be here
Outcomes were here
Functional
recovery
Remission
Response
50% improvement in a validated
depression rating scale from
baseline (e.g., HAM-D)
Not officially defined; varies
between studies (e.g., HAMD <7–10)
Adapted from: Nierenberg & DeCecco. J Clin Psychiatry 2001; 62 (Suppl 16): 5–9
7
8. Is remission the optimal outcome?
• Remission (as measured by symptom scales) is an
important target for treatment
• Residual symptoms are predictors of relapse,
chronicity and suicidality
• There are various remission criteria
• But, does remission = ‘health’ or functional recovery?
‘Health’ is a state of complete physical, mental, and social
well-being and not merely the absence of disease or infirmity.
World Health Organization
Preamble to the Constitution of the World Health Organization, 7 April 1948
8
12. Efficacy
All more effective than placebo (60-79%).
All have similar efficacy as TCAs (62-68%), when using 50%
reduction in HAM-D scores (response).
Dual-mechanism antidepressants may show better efficacy
when remission scores are used (HAM-D < 8).
All prevent relapse in depressed patients vs. placebo (20% vs.
50%).
13. Pharmacokinetic Parameters of the SSRI
Escitalopram Citalopram Fluoxetine Paroxetine Sertra
Half-life (hours)
27-32
35
96-386
21
26
Protein bound (%)
56%
80%
94%
95%
98%
Absorption altered
by fast or fed status
No
No
No
No
Yes
Linear kinetics
Yes
Yes
No
No
Yes
20-60
20-80
10-50
50-200
Dose range (mg/day) 10-20
for MDD
Van Harten, 1993; Preskorn, 1997; Preskorn, 1993;
Physician’s
Desk Reference, 2002; Forest Laboratories, data on file,
2002
14. Active Metabolites and the SSRIs
Active Metabolites
fluoxetine (1-4
days)
norfluoxetine (715 days)
No Active
Metabolites
sertraline,
paroxetine,
fluvoxamine,
citalopram
s-citalopram
15. es nops e R
Ot h
er
SS
R I’ s
Dose-response Curves
xa
ele
C
Dose
16. Potency and Selectivity of the
Human Monoamine Uptake Inhibition
SSRIs
5-HT
Selectivity
Uptake Inhibition
Ki (nmol/L)
Drug
5-HT
NE
DA
NE/5-HT Ratio
Escitalopram
2.5
6,514
>100,000
2,606
Citalopram
9.6
5,029
>100,000
524
Paroxetine
0.34
156
963
459
Sertraline
2.8
925
315
330
Fluoxetine
5.7
599
5,960
105
A lower Ki reflects greater potency
A higher selectivity ratio [Ki (nmol/L) NE/ Ki (nmol/L) 5-HT] reflects greater
specificity
less
selectiv
e
Owens et al., 2001
17. 5HT
What are the receptor types?
several families identified, eg.
5HT1 5HT2 5HT3 5HT4 5HT5 5HT6 5HT7
several subtypes of each family, eg.
5HT1A
5HT1B 5HT1c 5HT1D
18. Serotonin receptors:
5-HT1C has been renamed 5-HT2C to
indicate that it belongs within this
subfamily.
5HT 2
There are three subtypes, 5HT 2A , 5HT 2B ,
and 5HT 2C .
The 5HT 2A receptors mediate platelet
aggregation and smooth muscle
contraction.
19. Serotonergic Receptors
Receptor
Action
5 HT1a stimulation (agonist)
Improvement of affective symptoms
(Antidepressant and anxiolytic effect) +
effects on cognitive symptoms,
5HT1d, 5HT1f
5HT2a
accelerator of dopamine
Anti migraine
Cognition, target of atypical antipsychotics
- Brake of dopamine
5HT2b
Regulation of stomach contraction
5HT2c (previously 5HT1c)
Regulation of appetite, anxiety, seizures
- target of atypical antipsychotics
- Inverse agonist imrovement of negative
symptoms
20. Serotonergic Receptors
Receptor
Action
5 HT3
- Antagonists antiemetic, anxiolytic,
cognitive enhancement
5 HT4
Modulation of cognition and anxiety
5HT5a,b
Unknown
5 HT6
-negative and cognitive symptoms
-Target of antipsychotics
5 HT7
-negative and cognitive symptoms
- Circadian rhythms
21. Serotonergic Receptors
5‐ HT2 receptor stimulation
• Agitation
• Insomnia
• Sexual dysfunction
• Satiation
-5‐HT2A receptor normally works to inhibit (brake) the
release of the neurotransmitter dopamine.
5‐ HT3 receptor stimulation
• Nausea
• Diarrhea
• Headache
So, 5-HT2A antagonism – suppression of EPS
•
5HT1A is dopamine accelerator. However, 5HT2A is dopamine brake (opposite effect is on
glutamate).
So, 5-HT1A agonism – effects on cognitive symptoms, suppression of EPS
5-HT2A antagonism – suppression of EPS
22. Role of 5-HT in Nigrostriatal Dopaminergic Synapse
Sunstantia nigra
pars
compacta
Raphe
Nigrostriatal tract
5-HT
T
T
HT
HT
55-
-
5-HT2A
DA
D1
D2
Normal function
Caudate/putamen
23. Mechanism of therapeutic action:
pharmacologic properties
shared by all five SSRIs
Immediate blockade of serotonin transporter on
axon terminals and in somato-dendritic areas of
serotonergic neurone
Delayed down regulation/desensitisation of
somato-dendritic serotonin 1A receptors
Delayed disinhibition (i.e., ‘turning on’) of
serotonin release from axon terminals
24. SSRI
Half-life
antidepressants
Short: paroxetine & fluvoxamine (missed
doses can result in uncomfortable symptoms)
Moderate: sertraline, citalopram,
escitalopram
Long: fluoxetine (good for people who may
miss doses)
25. Mechanism of side effects:
pharmacologic properties
shared by all five SSRIs
Unwanted stimulation of undesired serotonin
receptor subtypes
‘Cost of doing business’
Especially clinically relevant are unwanted
stimulation of 5HT2A/2C and/or 5HT3/4 receptors
in various specific pathways and tissues
26. All five SSRIs lead to indirect
stimulation of serotonin 2A
receptors
Linked to short term mediation of:
– anxiety/panic attacks
– insomnia
– agitation/jitteriness
– sexual dysfunction (especially anorgasmia
and ejaculatory delay)
– apathy/anhedonia/decreased libido
– stimulation of 5HT2A receptors inhibits
dopamine release
27. All five SSRIs lead to indirect
stimulation of serotonin 2C
receptors:
(only fluoxetine also stimulates 5HT2C
receptors directly)
Mice without 5HT2C receptors are obese
Blockade of 5HT2C receptors, especially
simultaneous with blockade of histamine 1
receptors, is associated with weight gain
Acute stimulation can cause weight loss and
anxiety
Chronic stimulation can cause weight gain
28. All five SSRIs indirectly stimulate
serotonin 3 and 4 receptors
Decreased feeding (5HT3)
Loss of appetite/nausea (5HT3)
Vomiting (chemoreceptor trigger zone/5HT3)
Increased bowel motility (5HT3 and 5HT4)
29. SSRI
antidepressants
Side effects
Decreased sex drive and impaired sexual function
tend not to resolve with time
Nausea, diarrhea, anorexia, vomiting
- all increase with dose and can resolve with time
Weight gain (esp. paroxetine) after initial GI effects
Headache, dizziness, anxiety (esp. fluoxetine), rash,
insomnia, sedation, sweating, vivid dreams, tremor,
dry mouth (esp. paroxetine), bruising, ↑ prolactin
39. Secondary pharmacologic
properties of various SSRIs
5H
T2
C
DRI
m-AC
h
SSRI
σ
Stahl S. Essential Psychopharmacology, 2000
CYP 2D6
CYP 2D6
NO
S
RI
N
SRI
CY
P1
CY
A2
P
3A
3,
4
40. Potentially important secondary
binding properties for each SSRI
Fluoxetine and serotonin 2C stimulation
Sertraline and dopaminergic stimulation
Paroxetine and anticholinergic properties
Fluvoxamine and sigma properties
Citalopram and selectivity
43. Potential clinical relevance of
blocking muscarinic cholinergic
receptors
Possibly well tolerated in anxious patients, even
reducing anxiety before delayed SSRI actions begin
Possibly able to improve sleep early in treatment
Might be poorly tolerated in elderly with early cognitive
problems or Alzheimer’s disease
Might cause mild ‘anticholinergic’ side effects such as
constipation, dry mouth, blurred vision, sedation
Might cause more sexual dysfunction, (especially
erectile dysfunction), more weight gain and more
withdrawal problems
45. Potential clinical relevance of
interacting at sigma receptors
Possible anxiolytic actions
Possible antipsychotic actions
Possible increased GI side effects
47. Potential clinical relevance of
enhancing dopaminergic activity
Possible cognitive enhancement
Less prolactin elevation
Possibly less weight gain
Possibly too activating in some patients, thus
necessitating dose titration especially in those
with anxiety disorders
49. Potential clinical relevance of
selectivity without secondary
pharmacologic properties
Side effects and therapeutic effects predictable
based upon serotonergic mechanisms alone
Possibly less activation and less sedation than
SSRIs with secondary actions
Possibly faster onset due to lack of side effects
allowing rapid dose titration
Possibly good compliance at initiation of dosing if
serotonergic side effects minimal
50. SSRIs and the cytochrome P450
drug metabolising enzymes
Fluoxetine inhibits CYP450 2D6 and 3A4
Sertraline is a weak inhibitor of CYP450 2D6
Paroxetine inhibits CYP450 2D6
Fluvoxamine inhibits CYP450 1A2, 2C19 and 3A4
Citalopram is a weak inhibitor of CYP450 2D6
56. SSRIs/SNRIs
bind only to
the primary
The net result is
site
an intermittent
blockade of the
serotonin transporter
protein
57. Cipralex binds
both to the
primary and the
The net result is
allosteric site
Stronger and longer
binding to the serotonin
transporter protein
58. Explaining the
superior efficacy
of to both Primary binding site and vs.
Cipralex bindsCipralex allosteric site .
SSRIs SNRIs
Cipralex has a high affinity for the allosteric site
Cipralex is a more efficient blockade of the serotonin transporter protein .
This effect is the best explanation for the superior efficacy of Cipralex .
Cipralex is an extremely selective serotonin reuptake inhibitor
60. How does that fit with your clinical experience?
1.25
Escitalopram
1.20
Acceptability (OR)
1.15
Sertraline
Bupropion
Citalopram
1.10
1.05
Fluoxetine
Mirtazapine
1.00
Venlafaxine
0.95
0.90
0.85
●
Paroxetine
Duloxetine
Fluvoxamine
0.80
0.8
0.9
1.0
1.1
Efficacy (OR)
1.2
1.3
1.4
Cipriani et al. Lancet 2009; 373: 746–758
60
61. Summary: mechanism of action and
pharmacokinetics of SSRIs
All SSRIs share a common therapeutic mechanism
of action in depression, OCD, panic disorder,
social phobia and PTSD
All SSRIs can create unwanted side effects from
stimulating 5HT2A and 5HT3 receptors
Various SSRIs have potentially clinically significant
drug interactions, but these differ from one SSRI to
another
No two SSRIs have the same secondary binding
features, and this may account for why some
patients respond to one SSRI, or tolerate one SSRI,
better than another
63. Conclusion
• Functional improvements should be part of the patient
specific treatment goal
• There are differences among antidepressants
– Efficacy – tolerability – acceptability – safety - costeffectiveness
Antidepressants are different - choose
carefully!
63
65. Vortioxetine
Vortioxetine (formerly Lu AA21004) is described
as a multimodal antidepressant, working as a
- serotonin 5-HT3 and 5-HT7 receptor antagonist,
- 5-HT1b receptor partial agonist,
- 5-HT1a receptor agonist
- an inhibitor of the serotonin transporter SERT
(Brintellix, H. Lundbeck A/S).
Notas del editor
Should we treat the patients until they response? Until they get to remission? How to measure remission? How do you identify remission?
Do you take functionality into account?
Psychopharmacological considerations: matching the pharmacological properties of the drug to the presenting symptoms
Treatment moderator: need to discover treatment moderators which identify sub-populations of MDD patients who are more likely to experience the benefits of a given treatment (biologic markers, clinical markers) e.g. esc in severely depressed patients
DISCUSSION NOTES:
Evidence for treatment response has traditionally been the foundation for the approval of new antidepressants. Clinical rating scales such as the Hamilton Depression Rating Scale for Depression have been the gold standard for measuring patient response and remission, however, these measures can leave patients with residual symptoms of depression that can impair patient functioning.
Guidelines currently recommend that patients should be treated to symptomatic remission. With the recognition that patients in remission may still exhibit residual symptoms (which are associated with depressive relapse or recurrence), the bar is being raised once again, with the ultimate goal for the treatment of depression now moving towards functional recovery.
Despite sharing a similar mechanism of action, the SSRIs are a heterogeneous group of compounds, which can be distinguished from one another pharmacokinetically, as shown on this slide.
Drugs with longer half-lives, such as fluoxetine, citalopram, and escitalopram are likely to have fewer discontinuation symptoms if doses are missed or therapy is abruptly discontinued. Fluoxetine and norfluoxetine, its active metabolite, both contribute to the very prolonged half-life observed for fluoxetine.
Fluoxetine, paroxetine, and sertraline are highly protein bound ( 94%), whereas the protein binding of escitalopram (56%) is considerably less.
The absolute bioavailability of escitalopram, citalopram, fluoxetine, and paroxetine is not affected by food in the stomach. However, food does alter the pharmacokinetics of sertraline.
Paroxetine and fluoxetine have nonlinear pharmacokinetics over their usual dosing range, whereas those for escitalopram, citalopram and sertraline are linear. As a rule, nonlinear pharmacokinetics result when a drug induces or inhibits its own CYP450 metabolism and the patient can develop disproportionate increases in plasma levels with dose increases, which may result in increased risk of adverse effects. In drugs that demonstrate linear pharmacokinetics, a change in dose will produce a proportional change in plasma drug concentration.
The usual dose ranges for treatment of major depressive disorder (expressed as mg per day) are shown for the SSRIs.
References
1. van Harten JV. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1993;24:203-220.
2. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet. 1997;32(suppl 1):1-21.
3. Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry. 1993;54(suppl 9):14-34.
4. Physicians’ Desk Reference. 56th ed. Montvale, NJ: Medical Economics Company; 2002.
5. Data on file, Forest Laboratories, Inc., 2002
Owens and colleagues have assayed the relative potency of escitalopram and other SSRIs in the inhibition of the neuronal uptake of the monoamine neurotransmitters serotonin (5-HT), norepinephrine (NE) and dopamine (DA). A lower inhibitory constant (Ki) indicates that the compound produces inhibition at a lower concentration (represented in nanomoles per liter), i.e., it is more potent. Escitalopram and the other SSRIs are potent and selective serotonin reuptake inhibitors, but the serotonin selectivity ratio (comparing the extent of serotonin reuptake inhibition to the extent of inhibition of norepinephrine reuptake) indicates that escitalopram is the most selective inhibitor of serotonin reuptake studied to date.
Both serotonergic and noradrenergic systems are thought to play a role in depression and in its treatment, and the selectivity of a compound to inhibit one transporter over another has not been associated with greater clinical efficacy. However, some of the CNS-related adverse effects associated with antidepressant therapy such as agitation, anxiety, nervousness, insomnia, and even tremor may be due to an increase in noradrenergic tone. Thus, treatment with an agent that has minimal effect on the noradrenergic system may result in a lower incidence of these side effects.
Reference
1. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001;50(5):345-350.
Drug-drug interaction:
Interactions may arise when SSRIs are administrated with other drugs that share a common metabolic pathway via the Cytochrome P450 isoenzyme system.
Many psychotropics – including SSRIs - inhibit to varying degrees specific Cytochrom P450 isoenzymes involved in the elimination of drugs.
Escitalopram has a very low potential for drug-drug interactions, mainly because of the absent or very low inhibition of the Cytochrom P450 isoenzymes.
(Speaker note: Regarding CYP 2D6 – in vitro data did not reveal an inhibitory effect of escitalopram. However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram 20 mg/day.)
Citalopram is a racemic mixure of S-citalopram ( Escitalopram ) and R-citalopram . Only Escitalopram binds to the the primary binding site .
Both S- and R – citalopram bind to the allosteric binding site , like other SSRIs, R-Citalopram has a low affinity for the allosteric binding site .
On administration of Escitalopram , its interaction with the allosteric site results in a greater stabilization of escitalopram at the primary binding site compared to when R-citalopram is bound .
INclude again the slide on Ciprini with accepta and effic.